Waldman S A, Terzic A
Department of Pharmacology and Experimental Therapeutics, Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Mayo Clinic Center for Regenerative Medicine, Departments of Cardiovascular Medicine, Molecular Pharmacology and Experimental Therapeutics and Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA.
Clin Pharmacol Ther. 2017 Sep;102(3):373-377. doi: 10.1002/cpt.763.
Clinical Pharmacology & Therapeutics (CPT) is an established voice of the discipline, a trusted source of new knowledge showcasing discovery, translation, and application of novel therapeutic paradigms to advance the management of patients and populations. Identifying, evaluating, prioritizing, and disseminating the best science along the discovery-development-regulatory-utilization continuum are responsibilities shared through peer review. To enhance the uniformity of this essential component of quality assurance and innovation, and maximize the value of the journal and its contents to authors, reviewers, and the readership, we review key concepts concerning peer review as it specifically relates to CPT.
《临床药理学与治疗学》（CPT）是该学科的权威声音，是新知识的可靠来源，展示了新型治疗模式的发现、转化和应用，以推动患者和人群的管理。在发现-开发-监管-应用的连续过程中识别、评估、优先排序和传播最佳科学是通过同行评审共同承担的责任。为了提高质量保证和创新这一重要组成部分的一致性，并使期刊及其内容对作者、审稿人和读者的价值最大化，我们回顾了与同行评审相关的关键概念，因为它与CPT密切相关。
